Albumin

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Cirrhosis

Conditions

Cirrhosis, Ascites

Trial Timeline

Jul 1, 2009 → Apr 1, 2014

NCT ID

NCT00968695

About Albumin

Albumin is a approved stage product being developed by Grifols for Cirrhosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00968695. Target conditions include Cirrhosis, Ascites.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02479802	Phase 2	Completed	Nov 1, 2014	Jun 1, 2016	Amyotrophic Lateral Sclerosis
NCT02878733	Pre-clinical	Completed	Jan 1, 2012	Mar 1, 2013	Thoracic Surgery
NCT00968695	Approved	Completed	Jul 1, 2009	Apr 1, 2014	Cirrhosis

Competing Products

20 competing products in Cirrhosis

See all competitors

Product	Company	Stage	Hype Score
SYNB1020	Synlogic	Phase 1/2	33
peginterferon alfa-2a 180μg + peginterferon alfa-2a 90μg + ribavirin	Chugai Pharmaceutical	Phase 3	77
Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)	Shionogi	Phase 2	52
Mesenchymal Stem Cell	Rohto Pharmaceutical	Pre-clinical	23
Bumetanide + Furosemide	Johnson & Johnson	Phase 3	77
Mesenchymal stem cell	Rohto Pharmaceutical	Phase 1/2	41
Zibotentan	AstraZeneca	Phase 1	33
Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) + Part A: zibotentan (dose B) + dapagliflozin + Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) + Part B: placebo (matching zibotentan capsule) + dapagliflozin + Part B: zibotentan (dose A) + dapagliflozin + Part B: zibotentan (dose B) + dapagliflozin + Part B: zibotentan (dose C) + dapagliflozin	AstraZeneca	Phase 2	52
Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet) + Zibotentan + placebo (placebo matching dapagliflozin tablet) + Zibotentan + dapagliflozin	AstraZeneca	Phase 2	52
ARQ 197	Merck	Phase 1	33
Grazaoprevir/Elbasavir + Grazaoprevir/Elbasavir/RBV	Merck	Approved	85
Steroids + Basiliximab + Tacrolimus + Enteric-coated Mycophenolic acid (EC-MPA)	Novartis	Approved	85
Telbivudine + Enecavir + Adefovir	Novartis	Approved	85
Serelaxin + Placebo	Novartis	Phase 2	52
Terlipressin acetate + Serelaxin (RLX030)	Novartis	Phase 2	52
Pasireotide	Novartis	Phase 1	33
HPN-100 + Placebo	Amgen	Phase 2	51
Placebo Comparator + Experimental: Seladelpar 50 mg + Experimental: Seladelpar / MBX-8025 200 mg	Gilead Sciences	Phase 2	51
TDF/FTC/LPV/r + Placebo	Gilead Sciences	Pre-clinical	22
MBX-8025 2 mg Capsule + MBX-8025 5 mg Capsule + MBX-8025 10 mg Capsule	Gilead Sciences	Phase 2	51

Other Products from Grifols

Tetanus Immune Globulin (Human) + Diphtheria-Tetanus Toxoids AdsorbedApproved

Alphanate SD/HTApproved

(100 ml of Albumin 25%)Approved

IVIGApproved

FVIII + EmicizumabApproved